Literature DB >> 34120141

NK and NKT cells have distinct properties and functions in cancer.

Xia Liu1, Lingyun Li1, Fusheng Si1, Lan Huang1, Yangjing Zhao1, Chenchen Zhang1, Daniel F Hoft1,2, Guangyong Peng3,4.   

Abstract

Natural killer (NK) and natural killer T (NKT) cells are two important cell subsets of the innate immune system. NK and NKT cells share many phenotypes and functions for anti-tumor immunity; however, the dynamic changes in phenotypes and functional interactions within the tumor microenvironment during tumor development and progression are unknown. Here we report that NK and NKT cells have distinct properties, metabolic profiles, and functions during tumor development. Using the mouse E0771 breast cancer and B16 melanoma models, we found that both NK and NKT cells are dynamically involved in the immune responses to cancer but have distinct distributions and phenotypic profiles in tumor sites and other peripheral organs during the course of tumor development and progression. In the early stages of tumor development, both NK and NKT cells exhibit effector properties. In the later cancer stages, NK and NKT cells have impaired cytotoxic capacities and dysfunctional states. NK cells become senescent cells, while NKT cells, other than invariant NKT (iNKT) cells, are exhausted in the advanced cancers. In contrast, iNKT cells develop increases in activation and effector function within the breast tumor microenvironment. In addition, senescent NK cells have heightened glucose and lipid metabolism, but exhausted NKT cells display unbalanced metabolism in tumor microenvironments of both breast cancer and melanoma tumor models. These studies provide a better understanding of the dynamic and distinct functional roles of NK and NKT cells in anti-tumor immunity, which may facilitate the development of novel immunotherapies targeting NK and NKT cells for cancer treatment.

Entities:  

Mesh:

Year:  2021        PMID: 34120141     DOI: 10.1038/s41388-021-01880-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

Review 1.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

Review 2.  The three main stumbling blocks for anticancer T cells.

Authors:  Lukas Baitsch; Silvia A Fuertes-Marraco; Amandine Legat; Christiane Meyer; Daniel E Speiser
Journal:  Trends Immunol       Date:  2012-03-23       Impact factor: 16.687

Review 3.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 4.  Location and cellular stages of natural killer cell development.

Authors:  Jianhua Yu; Aharon G Freud; Michael A Caligiuri
Journal:  Trends Immunol       Date:  2013-09-19       Impact factor: 16.687

Review 5.  Mouse CD1-specific NK1 T cells: development, specificity, and function.

Authors:  A Bendelac; M N Rivera; S H Park; J H Roark
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 6.  Checkpoint inhibitors in breast cancer - Current status.

Authors:  Anne Polk; Inge-Marie Svane; Michael Andersson; Dorte Nielsen
Journal:  Cancer Treat Rev       Date:  2017-12-14       Impact factor: 12.111

Review 7.  T Cell Dysfunction in Cancer.

Authors:  Daniela S Thommen; Ton N Schumacher
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

Review 8.  Checkpoint Inhibitors in the Treatment of Breast Cancer.

Authors:  Tomas G Lyons; Maura N Dickler; Elizabeth E Comen
Journal:  Curr Oncol Rep       Date:  2018-04-30       Impact factor: 5.075

Review 9.  Immunotherapy in Breast Cancer: the New Frontier.

Authors:  Zishuo I Hu; Heather L McArthur
Journal:  Curr Breast Cancer Rep       Date:  2018-04-16

Review 10.  Mechanisms of immune evasion in breast cancer.

Authors:  Joshua P Bates; Roshanak Derakhshandeh; Laundette Jones; Tonya J Webb
Journal:  BMC Cancer       Date:  2018-05-11       Impact factor: 4.430

View more
  4 in total

Review 1.  Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.

Authors:  Rosalia Busà; Matteo Bulati; Ester Badami; Giovanni Zito; Daniela Claudia Maresca; Pier Giulio Conaldi; Giuseppe Ercolano; Angela Ianaro
Journal:  Front Cell Dev Biol       Date:  2022-05-26

Review 2.  Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells.

Authors:  Renata de Freitas Saito; Luciana Nogueira de Sousa Andrade; Silvina Odete Bustos; Roger Chammas
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

3.  A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.

Authors:  Jian-Xuan Sun; Chen-Qian Liu; Jin-Zhou Xu; Ye An; Meng-Yao Xu; Xing-Yu Zhong; Na Zeng; Si-Yang Ma; Hao-Dong He; Zong-Biao Zhang; Shao-Gang Wang; Qi-Dong Xia
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

Review 4.  Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy.

Authors:  Pei-Heng Li; Xiang-Yu Kong; Ya-Zhou He; Yi Liu; Xi Peng; Zhi-Hui Li; Heng Xu; Han Luo; Jihwan Park
Journal:  Mil Med Res       Date:  2022-09-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.